At a Glance
| Property | Detail |
|---|---|
| What it is | Synthetic 7-amino-acid fragment (LKKTETQ) of thymosin beta-4 (Tβ4), the actin-binding region |
| Evidence Level | Limited — animal studies and clinical observation; no human dose-finding trials. Small human trials exist only for full-length Tβ4 [5][6][7][8] |
| Typical Loading Dose | 2-2.5 mg SC, twice weekly for 4-6 weeks (community compilations: up to 4-8 mg per week) |
| Typical Maintenance Dose | 2 mg SC, once weekly or biweekly |
| Cycle Length | 8-12 weeks total (loading + maintenance) |
| Route | Subcutaneous injection |
| Main known or theoretical risks | Pro-migratory and pro-angiogenic biology with a theoretical cancer-growth concern; unknown purity of grey-market vials; injection-related infection |
| Regulatory Status | Not approved by the FDA or EMA for any indication; prohibited at all times under WADA 2026 S2.3 |
Protocol Table: Dose, Route, Timing and Basis
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
One row per use case. Basis: Trial (published human study, PMID), Practice protocol (reported by at least two independent compilations), Anecdotal (community reports only). No human study has tested the TB-500 fragment itself; the only Trial row below used full-length thymosin beta-4.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Injury recovery, loading (the protocol in this guide) | 2-2.5 mg | SC, abdominal or near the injury | Twice weekly | 4-6 weeks, then maintenance | Practice protocol (Peptide Protocol Wiki: 2-5 mg twice weekly; Peptide DB: 2-3 mg twice weekly) |
| Loading, upper end of common practice | 4-8 mg per week, split into 2-3 injections | SC | 2-3 times weekly | 4-6 weeks | Practice protocol (Peptide Protocol Wiki, most reported protocol; Peptide DB: 3-4 mg 2-3 times weekly for chronic problems) |
| Serious injury or after surgery | 3-5 mg per injection (some report 5-10 mg) | SC, near the site | 3 times weekly | 4-8 weeks | Anecdotal (Peptide DB; Peptide Protocol Wiki, listed as niche) |
| Maintenance | 2 mg (up to 4 mg) | SC | Once every 1-2 weeks (Peptide DB: 1-2 times weekly) | 4-6 weeks or ongoing | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| Combined with BPC-157 (“Wolverine” stack) | TB-500 2-2.5 mg twice weekly + BPC-157 250-500 mcg daily | SC | As listed | 4-8 weeks | Practice protocol (Peptide DB stack page; Peptide Protocol Wiki) |
| Safety of full-length thymosin beta-4 (not TB-500) | 42, 140, 420 or 1,260 mg | IV | Once daily | 14 days | Trial (phase 1, healthy volunteers, safety only; no dose-limiting toxicity; PMID 20536472) |
The phase 1 doses look enormous next to practice doses because they are a different molecule given intravenously to measure tolerability, not to treat anything. They tell you that full-length thymosin beta-4 was tolerated over two weeks; they do not tell you what dose of the fragment does anything in a human tendon.
Technique, reconstitution and storage are in the peptide injection guide.
What TB-500 Is and What It Does
Thymosin beta-4 is a 43-amino-acid protein present in almost every human cell. Its main job is to bind actin, the protein that forms the cell’s internal scaffold, and so control how cells change shape and move. That makes it relevant wherever cells need to migrate: wound closure, new blood vessel formation, repair of the cornea and the heart.
TB-500 is a synthetic copy of a short stretch of Tβ4, the part thought to carry much of the actin-binding activity. It is cheaper to make than the full protein. Whether it reproduces the full protein’s effects in people has never been tested.
This distinction matters for dosing because most of the published research uses full-length Thymosin Beta-4, not the TB-500 fragment. When translating study doses to TB-500 protocols, we are making an additional assumption — that the fragment retains equivalent potency to the relevant region of the full-length protein. The animal data supports this assumption, but it has not been rigorously validated in humans.
The animal findings for full-length Tβ4 are substantial:
- Skin wounds. In rats, topical or injected Tβ4 accelerated wound closure [1].
- Angiogenesis and hair. Tβ4 promoted new vessel growth and hair follicle activity in animal models [2].
- Cornea. In mice, Tβ4 improved corneal healing and reduced inflammation after alkali injury [3].
- Heart. In mice, Tβ4 improved cardiac cell survival and migration after infarction [4].
What the Evidence Shows
Preclinical
Consistent and biologically coherent for full-length Tβ4 in rodents [1][2][3][4]. It says little about the TB-500 fragment, and nothing directly about dose in humans.
Human (all with full-length Tβ4, not TB-500)
| Study | Design | n | What was studied | Finding | Certainty |
|---|---|---|---|---|---|
| Ruff 2010 [6] | Randomised, placebo-controlled phase 1, healthy volunteers | 40 | Intravenous synthetic Tβ4, single and 14-day repeated dosing, ascending cohorts | Adverse events infrequent and mild to moderate; no dose-limiting toxicity | Low: short-term safety only, no efficacy outcome |
| Wang 2021 [7] | Randomised, double-blind phase 1, healthy Chinese volunteers | 54 in the single-dose part, plus a multiple-dose cohort | Intravenous recombinant human Tβ4 (NL005) | Well tolerated in the short term | Low: safety and pharmacokinetics only |
| Sosne 2015 [5] | Randomised phase 2, severe dry eye | Small | Tβ4 eye drops (RGN-259) | Improvement in some signs and symptoms | Low: small trial, topical eye use only |
| Zhang 2025 [8] | Mouse study plus randomised trial after STEMI and PCI | 96 in the trial | Recombinant human Tβ4 after primary PCI | Smaller infarcts at 90 days in the 43 patients dosed within 8 h of PCI; no significant difference in infarct size across all 96 | Low: single trial, subgroup signal |
None of these trials used TB-500 or subcutaneous injection for muscle or tendon injury. The protocols below come from practice, not from these trials.
How Should You Dose TB-500?
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
Let me be direct: the dosing protocols for TB-500 tissue repair peptide are not based on human pharmacokinetic studies or dose-finding clinical trials. They are derived from allometric scaling of animal data, extrapolation from the Thymosin Beta-4 (full-length protein) research, and years of accumulated clinical observation. This is the reality for most peptide therapies, and you should understand it before committing to a protocol.
What I can tell you is that the loading-and-maintenance approach has emerged as the most widely used protocol across clinical practices, and there are logical reasons for this structure. Here is what the evidence shows, where it comes from, and how it translates to practical application.
The Loading Phase
The loading phase is the initial period of higher-frequency dosing designed to establish tissue saturation and initiate the repair process.
Standard Loading Protocol
| Parameter | Recommendation |
|---|---|
| Dose | 2-2.5 mg per injection |
| Frequency | Twice weekly (e.g., Monday and Thursday) |
| Duration | 4-6 weeks |
| Route | Subcutaneous injection |
| Injection site | Abdominal fat or near injury site |
This is the lower end of what people use. Community compilations most often report 4-8 mg per week split into 2-3 injections for 4-6 weeks (Practice protocol), and 3-5 mg per injection three times weekly for 4-8 weeks after a serious injury or surgery, with some reports of 5-10 mg (Anecdotal). Each figure and its source is in the protocol table above.
Why a Loading Phase?
The rationale for loading is based on the pharmacokinetics of tissue repair. When TB-500 promotes cell migration and actin organization in damaged tissue, the initial response requires establishing sufficient peptide concentration to overcome the threshold for biological activity. Think of it as filling a reservoir — once tissue levels are adequate, less peptide is needed to maintain them.
No human study has tested a loading phase against a flat schedule. The structure is a practice convention built on this rationale.
Dosing by Body Weight
TB-500 dosing in clinical practice is not strictly weight-adjusted. However, for patients at the extremes of body weight, some practitioners make modifications:
| Body Weight | Loading Dose |
|---|---|
| Under 65 kg | 1.5-2 mg, twice weekly |
| 65-90 kg | 2-2.5 mg, twice weekly |
| Over 90 kg | 2.5 mg, twice weekly |
These adjustments are based on clinical judgment, not pharmacokinetic modeling. Most adult protocols stay within the 2-2.5 mg range regardless of body weight.
The Maintenance Phase
After the loading phase, the frequency of administration is reduced. The goal is to sustain tissue-level peptide availability while the repair process continues, without the intensity of the loading period.
Standard Maintenance Protocol
| Parameter | Recommendation |
|---|---|
| Dose | 2 mg per injection (up to 4 mg in community compilations) |
| Frequency | Once weekly or once every two weeks (Peptide DB lists 1-2 times weekly) |
| Duration | 4-6 weeks, or ongoing |
| Route | Subcutaneous injection |
When to Transition from Loading to Maintenance
The transition typically occurs at 4-6 weeks, based on clinical response. Signs that the loading phase has been effective and maintenance is appropriate include:
- Measurable improvement in pain, range of motion, or function
- Imaging evidence of tissue repair (if applicable)
- Reduction in inflammation markers (if being monitored)
If there is no meaningful response after 6 weeks of loading, extending the loading phase is unlikely to produce a different outcome. That is the point to reassess the diagnosis, consider whether the injury is amenable to peptide therapy at all, and look for other contributing factors.
Cycling Protocols
Standard Cycle
| Phase | Duration | Dose | Frequency |
|---|---|---|---|
| Loading | Weeks 1-4 | 2.5 mg SC | Twice weekly |
| Maintenance | Weeks 5-8 | 2 mg SC | Once weekly |
| Rest | Weeks 9-12 | None | — |
| Reassess | Week 12 | — | Repeat cycle if needed |
Extended Cycle for Chronic Conditions
| Phase | Duration | Dose | Frequency |
|---|---|---|---|
| Loading | Weeks 1-6 | 2 mg SC | Twice weekly |
| Maintenance | Weeks 7-12 | 2 mg SC | Once weekly |
| Taper | Weeks 13-14 | 2 mg SC | Every 2 weeks |
| Rest | Weeks 15-18 | None | — |
Why Cycle?
The reasons for cycling TB-500 parallel those for other peptides:
-
Possible desensitization. No study has shown tolerance to TB-500, and no specific receptor for it has been identified. The rest period is a precaution borrowed from other peptides, not a response to a known effect.
-
Assessment windows. The rest period provides an opportunity to evaluate whether the healing achieved during the active cycle is durable and whether additional cycles are needed.
-
Safety conservatism. Without long-term continuous-use safety data, intermittent use is the more prudent approach.
Injection Technique and Practical Considerations
Reconstitution
TB-500 is typically supplied as a lyophilized powder. Reconstitution protocol:
- Add bacteriostatic water to the vial — 1-2 mL depending on desired concentration
- Swirl gently; do not shake
- Allow to dissolve completely (may take 5-10 minutes)
- Store reconstituted peptide refrigerated at 2-8°C
- Use within 3-4 weeks
Concentration Table
| Vial Size | Water Added | Concentration | 2 mg = | 2.5 mg = |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 0.4 mL (40 units) | 0.5 mL (50 units) |
| 5 mg | 2 mL | 2.5 mg/mL | 0.8 mL (80 units) | 1.0 mL (100 units) |
| 10 mg | 2 mL | 5 mg/mL | 0.4 mL (40 units) | 0.5 mL (50 units) |
Injection Site
TB-500 is administered subcutaneously. Unlike BPC-157 peptide therapy, where local injection near the injury site is often recommended, TB-500 is considered to distribute systemically regardless of injection site. This is because Tb4’s primary mechanism — actin regulation and promotion of cell migration — is not dependent on local tissue concentration in the same way that BPC-157’s VEGF upregulation may be.
That said, some clinicians still prefer injecting near the injury site. There is no data demonstrating superiority of either approach. The abdomen remains the most practical injection site for most patients. An exception is scalp-directed therapy: when TB-500 is used as part of a peptide hair restoration protocol, some practitioners administer it via mesotherapy directly into the scalp dermis to maximize local concentration alongside systemic dosing.
Combination with BPC-157
The combination of TB-500 and BPC-157 — sometimes called the “recovery stack” — is one of the most common peptide combinations in clinical use. The rationale is mechanistic complementarity:
| Peptide | Primary Mechanism | Strength |
|---|---|---|
| TB-500 | Actin regulation, cell migration, anti-fibrotic | Tissue remodeling, reducing scar formation |
| BPC-157 | Angiogenesis, growth factor modulation, NO system | Blood vessel formation, growth factor support |
Combination Protocol
| Peptide | Loading Phase | Maintenance Phase |
|---|---|---|
| TB-500 | 2-2.5 mg SC, 2x/week (weeks 1-4) | 2 mg SC, 1x/week (weeks 5-8) |
| BPC-157 | 250-500 mcg SC, 1x/day (weeks 1-6) | 250 mcg SC, 1x/day (weeks 7-8) |
For a detailed comparison of these two peptides, see BPC-157 vs TB-500: Which Healing Peptide and When.
Known and Theoretical Risks
- Cancer biology. The same properties that make Tβ4 attractive for repair, cell migration and new vessel growth, are properties tumours exploit. In laboratory studies, Tβ4 promoted invasion and migration of human colorectal cancer cells [10]. This does not show that TB-500 causes cancer. It does mean that people with a current or past cancer, or with an undiagnosed mass, are exactly the people in whom an untested pro-migratory peptide is hardest to justify.
- No long-term data. The longest human Tβ4 exposures in the trials above are measured in weeks.
- Product quality. Vials sold as “research peptides” are not manufactured or tested to pharmaceutical standards. In test purchases of another injectable peptide from illegal online sellers, purity was a fraction of the label and endotoxin was found in every sample [11].
- Immunogenicity and impurities. FDA notes that compounded TB-500 “may pose risk for immunogenicity” because of aggregation and peptide-related impurities [9].
- Injection-related harm. Any non-sterile injection can cause abscesses and skin infections. Injecting near an injured joint or tendon adds the risk of deeper infection.
- Anti-doping. A positive test carries sanctions regardless of the reason for use.
Regulatory Status
- United States. Not FDA-approved. FDA’s page on bulk substances that may present significant safety risks (content current as of 22 April 2026) lists “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among substances previously in category 2 whose compounding nominations were withdrawn, and states that FDA “lacks important information regarding any safety issues raised by this drug” [9]. As of FDA’s May 2026 list it is not on the 503A bulks list and not in category 1.
- EU and Germany. Not authorised by the EMA or by Germany’s BfArM. Labelling a product “research use only” does not make it an approved medicine or a product tested in people.
- Sport. Prohibited at all times under WADA 2026 S2.3, which names “Thymosin-ß4 and its derivatives e.g. TB-500” [12]. If you are a competitive athlete subject to anti-doping testing, TB-500 is not an option.
What the Evidence Does Not Tell Us
Thymosin Beta-4 has consistent tissue repair effects across numerous animal models. Here is what that evidence does not tell us:
- Whether the TB-500 fragment has identical potency to full-length Tb4 in humans
- The optimal loading duration for different injury types
- Whether twice-weekly dosing is superior to three-times-weekly or once-weekly during loading
- Long-term safety of repeated cycles
- Interaction with other medications
I treat these unknowns with respect rather than dismissal, and I never overstate the quality of the evidence behind the protocols.
When to Talk to a Physician
- For a tendon, ligament or muscle injury that is not healing: ask for a proper diagnosis (examination, ultrasound or MRI where indicated) and a structured rehabilitation plan. Load management and physiotherapy have far better evidence than any injectable peptide.
- If you are already using TB-500, tell your physician, especially before surgery, imaging for a mass, or cancer screening.
- Seek care promptly for redness, warmth, swelling or fever after an injection, or for any new lump.
- If you want access to an investigational peptide, look for a registered trial on ClinicalTrials.gov or the EU Clinical Trials Register.
The Bottom Line
TB-500 dosing follows a loading-and-maintenance structure: typically 2-2.5 mg subcutaneously twice weekly for 4-6 weeks, followed by 2 mg once weekly for an additional 4-6 weeks. Many users load higher, at 4-8 mg per week, and some use 3-5 mg three times weekly after serious injury (see the protocol table for the basis of each). All dosing is extrapolated from animal data and clinical experience. The loading approach is logical based on tissue repair biology but has not been validated in human dose-finding trials, and the human trials that exist used full-length thymosin beta-4, not the fragment. Work with a qualified physician, cycle appropriately, and maintain realistic expectations.
For the broader picture, see TB-500: Thymosin Beta-4 Fragment for Recovery and TB-500 for Tendon and Ligament Repair. For a comparison with the other “healing peptide”, see BPC-157 vs TB-500.
References
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PMID: 10469335.
- Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004. PMID: 15037013.
- Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002. PMID: 11950239.
- Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. PMID: 15565145.
- Sosne G, et al. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015. PMID: 25826322.
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PMID: 20536472.
- Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021. PMID: 34346165.
- Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction. Cardiovasc Res. 2025. PMID: 41229390.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. fda.gov
- Piao Z, et al. Thymosin β4 induces invasion and migration of human colorectal cancer cells through the ILK/AKT/β-catenin signaling pathway. Biochem Biophys Res Commun. 2014. PMID: 25218472.
- Ashraf AR, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription. J Med Internet Res. 2024. PMID: 39509151.
- World Anti-Doping Agency. The 2026 Prohibited List. Valid 1 January 2026. wada-ama.org
Disclaimer: This article is for informational and educational purposes only. It summarises doses used in research and practice; it is not a prescription or individual medical advice. TB-500 is not approved by the FDA or EMA for any therapeutic indication and is prohibited by WADA. Consult a qualified physician before pursuing any peptide therapy.